FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to oncology and can be used for treating non-small-cell lung cancer (NSCLC). Combination according to invention includes 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione of formula (I):
and a human epidermal growth factor receptor tyrosine kinase inhibitor (EGFR). Pharmaceutical composition according to invention includes 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione in combination with an EGFR tyrosine kinase inhibitor and one or more pharmaceutically acceptable excipients. Use of the declared combination concerns treating NSCLC.
EFFECT: use of inventions enables to inhibit growth and regress the tumour by synergetic action of the combination and recovery of tumour cell sensitivity to EGFR tyrosine kinase inhibitor by 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione.
9 cl, 1 dwg
| Title |
Year |
Author |
Number |
| NOVEL SALT OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]1,3-THIAZOLIDINE-2,4-DIONE, PREPARATION THEREOF AND FORMULATIONS CONTAINING SAME |
2014 |
- Le-Floik Aleksandr
- Gidotti Zherom
- Leteller Filipp
|
RU2680826C9 |
| 2-(2-OXOINDOLIN-3-YLIDENE)METHYL-5-(2-HYDROXY-3-MORPHOLIN-4-YLPROPYL)-6,7-DIHYDRO-1-H-PYRROLE[3,2-C]PYRIDIN-4(5H)-ONE COMPOUNDS AND USE THEREOF AS PROTEIN KINASE INHIBITORS |
2008 |
- Tan Pehn Chzho
- Jan Tszjaljan
- Su Idun
- Chzhao Futsjan
|
RU2472792C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS FOR CANCER TREATMENT |
2007 |
- Berke Gregori
- Linnartts Ronald Richard
- Makshikhi Pol M. Dzh.
- Versejs Richard Uill'Jam
- Vartmann Markus
|
RU2449788C2 |
| 1-SULFONYL-1,3-DIHYDROINDOLE-2-ONES, PHARMACEUTICAL COMPOSITIONS (VARIANTS), METHOD FOR THEIR PREPARING AND APPLYING |
2003 |
- Ivashchenko A.V.
- Khvat Aleksandr Viktorovich
- Kravchenko D.V.
- Tkachenko S.E.
- Okun' Il'Ja Matusovich
|
RU2259999C2 |
| NONHYGROSCOPIC CRYSTALLINE 5-[(Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]-N-[(2S)-2-HYDROXY-3-MORPHOLIN-4-YLPROPYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALEATE SALT, PHARMACEUTICAL COMPOSITION AND METHOD FOR CANCER TREATMENT |
2004 |
- Blasko Andrej
- Tszin' Tsinvu
- Lu Tsjun'
- Morejdzhis Majkl Ehntoni
- Song Dong
- Vondervell Brenda S'Ju
|
RU2319702C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER |
2007 |
- Berk Gregori Piter
- Linnartts Ronald Richard
- Manli Pol U.
- Versejs Richard Uill'Jam
|
RU2452492C2 |
| NEW INDOLIZINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
2013 |
- Le-Digare Terri
- Kasara Patrik
- Stark Zherom-Benua
- Anlen Zhan-Mishel
- Dejvidson Dzhejms Eduard Pol
- Marri Dzhejms Bruk
- Grem Kristofer Dzhon
- Chen Itszen
- Zhenes Olive
- Khikman Dzhon
- Depil Stefan
- Le-Tiran Arno
- Niergesh Miklosh
- De-Nantej Gijom
|
RU2646223C2 |
| HETEROCYCLIC NITROGEN PYRROLE DERIVATIVES, PRODUCING THEM AND PHARMACEUTICAL APPLICATION |
2008 |
- Tan Pehn Chzho
- Su Idun
- Li Jali
- Chzhan Lehj
- Chzhao Futsjan
- Jan Tszjaljan
- Chzhou In
- Bieh Pinjan'
- Tsjan' Guan'Tao
- Tszjuj Mingan
|
RU2473543C2 |
| ANTICANCER PHARMACEUTICAL COMPOSITION |
2007 |
- Fudzivara Kosaku
- Simazaki Naomi
|
RU2419430C2 |
| IMIDE MODULATORS OF PROTEOLYSIS AND METHODS FOR USING THEM |
2015 |
- Kruz Krejg
- Kryu Endryu P.
- Dun Khantsin
- Van Tszin
- Tsian Imin
- Tszin Mejchzhun
|
RU2738833C2 |
